Mumbai: Ajanta Pharmaceuticals has signed an licensing contract with Canada-based Prollenium Medical Technologies to exclusively market the latter’s dermal filler ‘Revanesse’ in the Indian market.

A message from Ajanta Pharmaceuticals said that the Prollenium Technologies has its proficiency in “medical aesthetics.”

The note added that revanesse adds volume and polishes out deficiencies in the skin and also helps protect delicate skin areas from maturating.

The company said that the total Indian dermatology market is projected at Rs 1,300 crore.

Ajanta Pharma shares gained more than 8 per cent at Rs 108.95 on the Bombay Stock Exchange (BSE).